Monoclonal antibodies (MAbs) to human immunodeficiency virus type 1 were produced. Two antibodies reacted with the 17-kilodalton core protein (p17) of the virus and with its polyprotein precursor. To various degrees, each MAb neutralized infection by the cell-free virus. With a series of sequential overlapping hexapeptides which represent the p17 gene product, the epitopes identified by the MAbs were defined. The epitopes localize to overlapping regions near the amino terminus of the protein. Soluble synthetic peptides which span the antibody-binding sites of interest were demonstrated to competitively inhibit the reactivity of p17 MAbs, thus confirming the location of virus-neutralizing sites within the core protein.
Human immunodeficiency virus type 1 (HIV-1) is tropic for cells that express the CD4 molecule and is the etiologic agent associated with acquired immunodeficiency syndrome. In vitro infection by HIV-1 can be blocked by antibodies obtained from sera of infected individuals (7, 17, 26) , although a precise relationship between antibody titers and disease course is not apparent.
Several reports have also demonstrated that HIV-1-neutralizing antibodies to various immunogens, including glycoprotein extracts (10) , recombinant proteins (8, 9) , and synthetic peptides (6, 7, 13) , can be developed. These antibodies react with HIV-1 env gene products, indicating the role of viral surface glycoproteins and cell receptor interactions. In addition, antibodies to the CD4 molecule are capable of inhibiting virus-binding activity, as are anti-idiotypic reagents to these antibodies (2) .
Although HIV-1 envelope glycoproteins are of strong interest with respect to virus inhibition, recent information indicates that gag-encoded proteins participate as a target for the neutralizing immune response. For example, it has been demonstrated that core protein p17 is modified at the posttranslational level to express an amino-terminal myristic acid group (23) , thus increasing the hydrophobicity of the molecule. Also, antibodies to the thymic hormone thymosin al appear to inhibit HIV-1 infection in vitro (22) . Since amino acid sequence homology occurs between that hormone and the carboxy-terminal region of p17 (12, 22) , the role of p17 in immune recognition and virus neutralization warrants further examination.
The present study was initiated to define the characteristics of monoclonal antibodies (MAbs) to HIV-1 which demonstrated reactivity to core protein p17, to define their virus-neutralizing capacity, and to map the immunoreactive epitopes of interest.
MATERIALS AND METHODS
MAb production. HIV-1 was purified from the supernatant of a producer cell line as described previously (16). Virions were disrupted in detergent-high salt (0.5% Triton X-100, 0.6 M KCl) under sonication and then ether extracted to remove * Corresponding author. the detergent. Female BALB/c mice were primed with 100 ,ug of viral protein emulsified in complete Freund adjuvant and boosted at monthly intervals with 50 jig of protein in incomplete adjuvant. At 3 days after boost 4, the spleens were obtained for cell fusion. The fusion protocol, using Sp2/ 0-Agl4 myeloma cells in the presence of 50% polyethylene glycol, was as described previously (14) .
Immunologic assays. Western blotting (WB; immunoblotting) was performed essentially as described before (16), with antigen strips provided by DuPont, Biotechnology Systems Division, Wilmington, Del. Briefly, WB strips were incubated for 18 h at room temperature with MAbs at 10 ,ug/ ml. Strips were washed in PBS-T (50 mM sodium phosphate [pH 7.2], 150 mM sodium chloride, 0.05% Tween 20) and then allowed to react with biotin-labeled goat antibody to murine immunoglobulin G (IgG; Jackson Laboratory, West Grove, Pa.) for 1 h at 37°C. After the strips were washed, streptavidin-peroxidase conjugate (Jackson Laboratory) was applied for 0.5 h at 37°C. Washed strips were developed in a solution containing phosphate-buffered saline-0.01% 4-chloro-1-naphthol-0.03% hydrogen peroxide.
Solid-phase synthetic peptides were examined for immunoreactivity by enzyme immunoassay (EIA). Polyethylene pins with peptides on their surfaces (see below) were countercoated in EIA buffer (phosphate-buffered saline, 1% ovalbumin, 1% bovine serum albumin, 0.1% Tween 20) for 18 h at 4°C. After being washed with PBS-T (four times for 10 min each time), the pins were incubated in microplates containing a MAb or a control antibody, each at 10 jig/ml, for 18 h at 4°C. After the pins were washed as described above, incubation was allowed to proceed for 1 Epitope scanning. The strategy used for epitope scanning consisted of the construction of sequential, overlapping hexapeptides which completely spanned the entire HIV-1 p17 amino acid sequence (4) . Since the anti-p17 MAbs under study strongly reacted with the prototype human T-cell lymphotropic virus type IIIB strain of HIV-1, its published sequences were used to construct peptide homologs (18) .
Peptides were synthesized in situ on plastic pins which conform in configuration to a standard 96-well microplate by using reagents and a kit (Epitope Mapping Kit) provided by washed, and air dried. Included in the experiment were concurrently synthesized peptide controls with known reactivity to available antisera. These peptides represented the sequences Pro-Leu-Ala-Gln and Gly-Leu-Ala-Gln. One of these peptides (Pro-Leu-Ala-Gln) is known to react with an antibody to sperm whale myoglobin, while the other is nonreactive but similar in structure. These EIA-testable peptides were included in each assay run.
Soluble synthetic peptides. Peptides were synthesized by the strategy of Merrifield (11) at Peninsula Laboratories, Inc., Belmont, Calif. The acid-labile, tert-butyloxycarbonyl group was used for temporary amino-terminal protection. Peptides were cleaved from the resin with HF-anisole (9:1) containing 2% ethanedithiol and purified by gel filtration (Sephadex G-25 in 0.1 M acetic acid), followed by reversedphase high-performance liquid chromatography. The sequence of each peptide was confirmed by amino acid analysis.
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of incubation at 370C, the cells were washed and placed in culture in complete medium containing RPMI 1640-10% fetal bovine serum-antibiotics. Virus replication was monitored at 10 days by measuring reverse transcriptase activity (19) . Counts per minute were corrected for background levels of reverse transcriptase as constitutively released by the HUT-102 cells.
For some experiments, peripheral blood mononuclear cells prestimulated with phytohemagglutinin were used as the permissive cell substrate, as previously described (3). In brief, washed lymphocytes at 106 cells per ml were incubated for 3 days in the presence of 1 ,ug of PHA-P (Difco Laboratories, Detroit, Mich.). Thereafter, the washed cells were suspended in complete medium containing 10% interleukin-2 (Cellular Products, Inc., Buffalo, N.Y.) and 2 ,ug of Polybrene per ml. The lymphocyte cultures containing activated T cells were then used for virus transmission experiments.
RESULTS
Spleen cells from an animal immunized with HIV-1 lysate were subjected to cell fusion, and the resultant crude hybridoma cultures were screened for antibody activity by solidphase EIA and WB. Cultures of interest were cloned, reassayed, and subcloned. Three cloned lines were studied in more detail; two hybridomas secreted anti-p17 antibodies (clones 32/5.8/42 and 32/1.24.89), and one produced an antibody reactive with p24 (clone 32/5.17.76), each of the IgG class. On WB examination (Fig. 1) To study the biological activity of the MAbs, HIV-1 neutralization assays were performed. Assays were performed with cell-free virus which was allowed to propagate in HUT-102 permissive cells. In addition to the anti-core MAbs, the neutralizing capacities of IgGs purified from seropositive (HIV+ IgG) and seronegative (HIV-IgG) donors were evaluated. MAb 32/5.17.76 (anti-p24) and HIVIgG failed to perturb the infectivity of the cell-free virus (Fig.  2) . In contrast, submicrogram concentrations of HIV+ IgG and MAb 32/1.24.89 were potent inhibitors of virus replication. The other anti-p17 antibody (MAb 32/5.8.42) also demonstrated a significant level of virus inhibition, although at higher input levels of immunoglobulin. Indistinguishable results were obtained when phytohemagglutinin-stimulated peripheral blood lymphocytes were used as the permissive cells (Fig. 3) , indicating that antibody-mediated virus inhibition was a cell substrate-independent event.
To determine whether the two MAb reagents to p17 identify the same antigenic site on the core protein, antibody competition assays were run. The reactivity of biotin-conjugated MAb 32/1.24.89 versus solid-phase HIV-1 was undisturbed in the presence of 1,000-fold excess levels of the anti-p24 MAb (Fig. 4) . In contrast, complete binding inhibition was observed with homologous, unlabeled antibody 32/1.24.89. It is interesting that anti-p17 MAb 32/5.8.42 also produced significant inhibition (about 80%), indicating that these antibodies reacted with sterically related epitopes of the p17 molecule. Reciprocal-inhibition experiments (Fig.  4B ) yielded similar data.
To define precisely the p17 epitopes of interest, epitope scanning was performed with a series of overlapping hexapeptides which completely spanned the HIV-1 p17 gene product. The solid-phase peptides were individually screened for reactivity to each p17 MAb by EIA (Fig. 5) . The results clearly indicated that MAb 32/5.8.42 strongly bound to three adjacent peptides occupying the amino-terminal region of p17 and to a single hexapeptide much further downstream. MAb 32/1.24.89 produced a distinct pattern of binding (Fig. 5) To confirm the data obtained from epitope scanning experiments, soluble peptides were synthesized which corresponded to the amino-terminal MAb 32/5.8.42-binding site (epitope A, residues 12 to 19), the MAb 32/1.24.89-binding site (epitope B, residues 17 to 22), and a region containing both binding sites (epitope A/B, residues 12 to 22); these synthetic peptides were termed SP-17-A, SP-17-B, and SP-17-A/B, respectively. Each soluble peptide was allowed to compete with solid-phase HIV-1 for binding of both MAbs. SP-17-A effectively inhibited the binding activity of MAb 32/5.8.42, exhibiting a 50% inhibitory dose of about 1 ,ug/ml (Fig. 6 ). This peptide was immunologically specific, inasmuch as no effect was noted on the reactivity of MAb 32/ 1.24.89. SP-17-B, corresponding to the binding site of MAb 32/1.24.89, was capable of inhibiting homologous antibody but only at very high concentrations (50% inhibitory dose, about 3.2 x 103 ,ug/ml), indicating a low-affinity interaction. However, the inhibition was immunologically specific. Further studied was a synthetic peptide which contained both MAb-binding sites. This peptide, SP-17-A/B, was a strong inhibitor of each anti-p17 antibody (Fig. 6) (18) . Core protein p17 is the N-terminal product of the polyprotein precursor and itself is modified posttranslationally at its amino terminus to express a myristic acid moiety (23) . This specific modification of the Nterminal gag protein has been shown for all human retroviruses (23) and likely imparts a significant function, such as integration within membrane components. Of therapeutic interest, antisera to thymosin have been shown to neutralize the in vitro infectivity of HIV-1 (22) , putatively because of cross-reactivity with p17. The crossreactivity observed may be a result of the partial sequence homology between the two molecules (12), although a recent investigation failed to demonstrate immunological relatedness between p17 and thymosin al (20) .
The present data clearly indicate that p17 represents a potential target for immunotherapy. Two 1, 18, 21, 24) .
The underlying mechanism of antibody-mediated virus inhibition remains to be determined. Previous investigations using antivirus antibodies have shown that certain domains of the gpl20 virus surface glycoprotein are prominent targets for neutralization (8) (9) (10) 13) . These antibodies, in addition to those reactive with binding sites of the CD4 receptor, effectively inhibit virus adsorption and subsequent penetration. Since p17 has not been shown to play a role in receptor binding, antibodies to that core protein are unlikely to prevent virus adsorption to CD4 and a distinct mechanism must exist. However, recent data indicate that antibodies to a conserved region of gpl20 not involved in receptor binding also can exert HIV-1 neutralization without affecting virus binding to the CD4 receptor (6) . It is conceivable that novel HIV-1 epitopes contribute to virus infection by interacting with undefined components of the T-cell membrane or the virus-processing machinery of the T cell (or both).
Yet to be defined is the role that neutralizing antibodies may play in prevention of HIV-1 infection and, relatedly, what antigens and epitopes must be present in a vaccine which will elicit effective immunity which is broadly reactive. Although the epitopes described here appear to be conserved in sequence, questions remain regarding their capacity to elicit fusion-inhibiting antibodies and antibodydependent cellular cytotoxicity. Also of considerable interest, the present antibodies may be of value in generating anti-idiotypic reagents which may represent immunogens more effective than short peptides.
